Prediction of Chemotherapy-Induced Peripheral Neuropathy in Patients with Lymphoma and Myeloma: the Roles of Brain-Derived Neurotropic Factor Protein Levels and A Gene Polymorphism
| Autor: | Rivka Sharon, David Azoulay, Roni Nasser, Netanel A. Horowitz, Sami Giryes |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Oncology
medicine.medical_specialty Vincristine medicine.medical_treatment 03 medical and health sciences 0302 clinical medicine Neurotrophic factors Internal medicine medicine 030212 general & internal medicine Multiple myeloma Chemotherapy Bortezomib business.industry non-Hodgkin lymphoma medicine.disease Lymphoma multiple myeloma Val66Met single-nucleotide polymorphism Peripheral neuropathy BDNF Neurology Chemotherapy-induced peripheral neuropathy Original Article Neurology (clinical) business 030217 neurology & neurosurgery medicine.drug chemotherapy-induced peripheral neuropathy |
| Zdroj: | Journal of Clinical Neurology (Seoul, Korea) |
| ISSN: | 1738-6586 |
| Popis: | Background and purpose Brain-derived neurotrophic factor (BDNF) is a neuronal growth factor that plays an essential role in the maintenance of the nervous system. We have evaluated the peripheral blood protein levels of BDNF and the valine-to-methionine substitution at codon 66 (Val66Met) single-nucleotide polymorphism (SNP) as potential biomarkers for the early recognition of chemotherapy-induced peripheral neuropathy (CIPN) in non-Hodgkin lymphoma and multiple myeloma patients. Methods CIPN was assessed in 45 patients at the diagnosis and during vincristine or bortezomib-based therapy using objective [reduced version of the Total Neuropathy Score (TNSr)] and subjective (FACT-GOG-NTx) tools. Depression was assessed using the Patient Health Questionnaire-9 (PHQ-9) questionnaire. BDNF protein levels and the Val66Met SNP were determined using ELISA and Sanger sequencing. Results The pretreatment BDNF protein level was inversely correlated with the maximum TNSr, FACT-GOG-NTx, and PHQ-9 scores in both genotypes. BDNF patients with the Val/Val genotype demonstrated significantly higher maximum FACT-GOG-NTx and PHQ-9 scores than those with the Val/Met and Met/Met genotypes (Met-BNDF carriers). Correlations between PHQ-9 and TNSr score were found only in Met-BDNF carriers, suggesting that peripheral neuropathy and depression coincide in Met-BDNF carriers. Conclusions Determining the BDNF protein levels before initiating chemotherapy might be a useful tool for CIPN risk assessment and preemptive dose modification. The present data should be validated in larger studies that include other neurotoxic agents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|